SCN8A and Parkinson disease: Previous studies have shown that SVHRSP exhibited multi-target neuroprotection by inhibiting NADPH oxidase/NLRP3 inflammasome and modulating microglial Nav1.6 channels to protect dopaminergic neurons in Parkinson’s disease [13,14,34], reducing oxidative stress and neuroinflammation in cognitive decline [15], and regulating NMDA receptors to exert antiepileptic effects [35].